Zoetis (NYSE:ZTS) Stock Price Expected to Rise, Piper Sandler Analyst Says

Zoetis (NYSE:ZTS) had its price objective boosted by investment analysts at Piper Sandler from $200.00 to $205.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 24.25% from the stock’s previous close.

ZTS has been the topic of several other research reports. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Trading Down 2.1 %

Shares of Zoetis stock opened at $164.99 on Thursday. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a market capitalization of $73.88 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company’s fifty day moving average price is $166.22 and its two-hundred day moving average price is $177.58.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis will post 6.07 EPS for the current year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC lifted its holdings in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $30,000. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the 3rd quarter worth $31,000. Finally, First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.